Pharmacokinetic Study of BAY3283142 with Atazanavir in Chronic Kidney Disease Patients

The primary objective of this study is to evaluate the pharmacokinetics of **BAY3283142** in healthy participants when co-administered with atazanavir. This involves assessing how the drug is absorbed, distributed, metabolized, and excreted, as well as determining the proportion of BAY3283142 that reaches the bloodstream when administered orally. Understanding these pharmacokinetic properties is clinically relevant as it provides essential information on the drug's behavior in the body, which is crucial for optimizing dosing regimens and ensuring safety and efficacy in future therapeutic applications, particularly in the context of **chronic kidney disease**.

The clinical trial involves participants diagnosed with **chronic kidney disease**. The study population includes both male and female subjects, with an age range categorized under code "3," which typically represents adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been detailed. Key inclusion or exclusion criteria are not specified in the available data.

The clinical trial is designed to evaluate the pharmacokinetics of **BAY3283142** when administered in conjunction with atazanavir in healthy participants. This study is a Phase 3 trial, characterized by a **randomized**, **double-blind**, and **controlled** design, ensuring the reliability and validity of the results. The trial is scheduled to commence recruitment on November 5, 2024, with an estimated completion date of December 19, 2024, indicating a total duration of approximately 1.5 months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups. Throughout the trial, several follow-up visits will be conducted to monitor the pharmacokinetic parameters and ensure participant safety. These visits will include assessments such as blood sampling and clinical evaluations. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the study's endpoints.

The expected length of participant involvement is aligned with the trial's overall duration, with specific timelines for each visit outlined in the study protocol. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial's design and procedures are structured to maintain scientific rigor while ensuring the safety and well-being of all participants.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on November 5, 2024, with an estimated completion date of December 19, 2024. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured protocol to ensure the collection and analysis of efficacy data is consistent and reliable. The trial's design and execution will adhere to the standards expected in a Phase 3 clinical trial, focusing on the evaluation of treatment effects in a larger patient population. The study will be conducted in accordance with regulatory requirements and ethical guidelines to ensure the integrity and validity of the efficacy data collected.